Daniel J. Stekhoven

Dr. Daniel J. Stekhoven

1. Director NEXUS Personalized Health Technologies, Head Clinical Bioinformatics, ETH Zurich, Switzerland</br> 2. SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2018 in BMC Medicine
Verified
Journal Article
Open access
PDF file
Holger FröhlichHolger Fröhlich
Holger Fröhlich
RBRudi Balling
Rudi Balling
NBNiko Beerenwinkel
Niko Beerenwinkel
OKOliver Kohlbacher
Oliver Kohlbacher
SKSantosh Kumar
Santosh Kumar
BZBlaz Zupan
Blaz Zupan
Personalized, precision, P4, or stratified medicine is understood as a medical approach in which patients are stratified based on their disease subtype, risk, prognosis, or treatment response using specialized diagnostic tests. The key idea is to base medical decisions on individual patient characteristics, including molecular and behavioral biomarkers, rather than on population averages. Personalized medicine is deeply connected to and dependent on data science, specifically machine learning (often named Artificial Intelligence in the mainstream media). While during recent years there has been a lot of enthusiasm about the potential of ‘big data’ and machine learning-based solutions, there exist only few examples that impact current clinical practice. The lack of impact on clinical practice can largely be attributed to insufficient performance of predictive models, difficulties to interpret complex model predictions, and lack of validation via prospective clinical trials that demonstrate a clear benefit compared to the standard of care. In this paper, we review the potential of state-of-the-art data science approaches for personalized medicine, discuss open challenges, and highlight directions that may help to overcome them in the future. There is a need for an interdisciplinary effort, including data scientists, physicians, patient advocates, regulatory agencies, and health insurance organizations. Partially unrealistic expectations and concerns about data science-based solutions need to be better managed. In parallel, computational methods must advance more to provide direct benefit to clinical practice.

28 August 2012 in Molecular Systems Biology
Verified
Journal Article
Open access
PDF file
KBKatja Baerenfaller
Katja Baerenfaller
CMCatherine Massonnet
Catherine Massonnet
SWSean Walsh
Sean Walsh
SBSacha Baginsky
Sacha Baginsky
PBPeter Bühlmann
Peter Bühlmann
WGWilhelm Gruissem
Wilhelm Gruissem
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

27 August 2013 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
ACAdrian Ciurea
Adrian Ciurea
ASAlmut Scherer
Almut Scherer
PEPascale Exer
Pascale Exer
JBJürg Bernhard
Jürg Bernhard
JDJean Dudler
Jean Dudler
OSon behalf of the Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
on behalf of the Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis
Objective: To evaluate the baseline characteristics of patients with radiographic axial spondyloarthritis (SpA; ankylosing spondylitis [AS]) and patients with nonradiographic axial SpA, to investigate determinants of anti–tumor necrosis factor (anti‐TNF) agent prescription on the background of a nonrestrictive reimbursement policy, and to assess the response to TNF inhibition.Methods: We compared the characteristics of radiographic axial SpA and nonradiographic axial SpA in 1,070 patients from the Swiss Clinical Quality Management (SCQM) Cohort who fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for axial SpA. By taking advantage of the situation that patients who are eligible for anti‐TNF treatment are preferentially enrolled in the SCQM Cohort for patients with AS/axial SpA, we explored parameters leading to the initiation of anti‐TNF treatment in single and multiple regression models and assessed treatment responses.Results: We confirmed a similar burden of disease (as determined by self‐reported disease activity, impaired function, and quality of life) in patients with nonradiographic axial SpA (n = 232) and those with radiographic axial SpA (n = 838). Patients with radiographic axial SpA had higher median levels of acute‐phase reactants and higher median AS Disease Activity Scores (ASDAS; 3.2 versus 3.0). Anti‐TNF treatment was initiated in 363 patients with radiographic axial SpA and 102 patients with nonradiographic axial SpA, preferentially in those with sacroiliitis on magnetic resonance imaging, peripheral arthritis, a higher C‐reactive protein (CRP) level, a higher ASDAS, and a higher Bath Ankylosing Spondylitis Disease Activity Index level. The ASAS criteria for 40% improvement responses at 1 year were higher in patients with radiographic axial SpA compared with those with nonradiographic axial SpA (48.1% versus 29.6%; odds ratio [OR] 2.2, 95% confidence interval [95% CI] 1.12–4.46, P = 0.02). The difference was smaller in the subgroups of patients with elevated baseline CRP levels (51.6% in patients with radiographic axial SpA versus 38.5% in those with nonradiographic axial SpA; OR 1.7, 95% CI 0.68–4.48, P = 0.29).Conclusion: The indications for treatment with anti‐TNF agents were comparable for patients with radiographic axial SpA and those with nonradiographic axial SpA. With the exception of patients with elevated CRP levels at baseline, higher rates of response to TNF inhibition were achieved in the group of patients with radiographic axial SpA than in the group with nonradiographic axial SpA.

22 July 2013 in Genome Research
Verified
Journal Article
Open access
PDF file
UOUlrich Omasits
Ulrich Omasits
MQMaxime Quebatte
Maxime Quebatte
DSDaniel J. Stekhoven
Daniel J. Stekhoven
CFClaudia Fortes
Claudia Fortes
BRBernd Roschitzki
Bernd Roschitzki
Christian AhrensChristian Ahrens
Christian Ahrens
Prokaryotes, due to their moderate complexity, are particularly amenable to the comprehensive identification of the protein repertoire expressed under different conditions. We applied a generic strategy to identify a complete expressed prokaryotic proteome, which is based on the analysis of RNA and proteins extracted from matched samples. Saturated transcriptome profiling by RNA-seq provided an endpoint estimate of the protein-coding genes expressed under two conditions which mimic the interaction ofBartonella henselaewith its mammalian host. Directed shotgun proteomics experiments were carried out on four subcellular fractions. By specifically targeting proteins which are short, basic, low abundant, and membrane localized, we could eliminate their initial underrepresentation compared to the estimated endpoint. A total of 1250 proteins were identified with an estimated false discovery rate below 1%. This represents 85% of all distinct annotated proteins and ∼90% of the expressed protein-coding genes. Genes that were detected at the transcript but not protein level, were found to be highly enriched in several genomic islands. Furthermore, genes that lacked an ortholog and a functional annotation were not detected at the protein level; these may represent examples of overprediction in genome annotations. A dramatic membrane proteome reorganization was observed, including differential regulation of autotransporters, adhesins, and hemin binding proteins. Particularly noteworthy was the complete membrane proteome coverage, which included expression of all members of the VirB/D4 type IV secretion system, a key virulence factor.

1 August 2014 in Journal of Proteomics
Verified
Journal Article
Closed access
EQErmir Qeli
Ermir Qeli
UOUlrich Omasits
Ulrich Omasits
SGSandra Goetze
Sandra Goetze
DSDaniel J. Stekhoven
Daniel J. Stekhoven
JFJuerg E. Frey
Juerg E. Frey
Christian AhrensChristian Ahrens
Christian Ahrens

9 August 2024 in Genome Biology
Verified
Journal Article
Open access
PDF file
PBPelin Icer Baykal
Pelin Icer Baykal
PLPawel Labaj
Pawel Labaj
FMFlorian Markowetz
Florian Markowetz
LSLynn M. Schriml
Lynn M. Schriml
DSDaniel J. Stekhoven
Daniel J. Stekhoven
NBNiko Beerenwinkel
Niko Beerenwinkel
In biomedical research, validating a scientific discovery hinges on the reproducibility of its experimental results. However, in genomics, the definition and implementation of reproducibility remain imprecise. We argue that genomic reproducibility, defined as the ability of bioinformatics tools to maintain consistent results across technical replicates, is essential for advancing scientific knowledge and medical applications. Initially, we examine different interpretations of reproducibility in genomics to clarify terms. Subsequently, we discuss the impact of bioinformatics tools on genomic reproducibility and explore methods for evaluating these tools regarding their effectiveness in ensuring genomic reproducibility. Finally, we recommend best practices to improve genomic reproducibility.